Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
In today's episode, we're exploring a breakthrough in the search for a treatment for sickle cell disease (SCD), a challenge that has long eluded medical researchers. Novartis has introduced a promising candidate in the form of a molecular glue degrader drug, designed to elevate fetal hemoglobin levels in SCD patients, as detailed in a recent publication in Science by Dr. Pamela Ting and her team at Novartis Biomedical Research. This innovative approach not only signifies a major advancement in SCD drug development but also underscores the expanding utility of degraders and molecular glues, which have been pivotal in oncology and immunology but are now showing efficacy in rare diseases. This development could potentially compete with genetic medicine approaches and hints at the therapeutic potential of epigenetic mechanisms, a field ripe for discovery.
📣🎙️ TODAY’S POCAST:
[ 0:07 ] Intro to Bowtied Biotech
[ 0:36 ] Sickle Cell Impact
[ 0:52 ] Novartis' New Drug
[ 1:05 ] Role of HBF
[ 1:46 ] Molecular Glue Explained
[ 2:05 ] Targeting WIZ Protein
[ 2:27 ] Preclinical Results
[ 2:49 ] Next Steps: Human Trials
[ 3:39 ] Beyond Sickle Cell
[ 4:44 ] Drug Development Shift
[ 5:19 ] Investment Potential
[ 5:33 ] Connected Discoveries
[ 5:58 ] Personalized Medicine
[ 6:42 ] Future of Medicine
[ 7:30 ] Closing Remarks
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post